Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPWVA5S0ZmbVhzc0w3UkFDUUNIbUtEYUdWVDJiNFZZRTI5YS1XRDdtVmE4bXU2ZGVJYjlieGJWdF9TS0N0QUlUUkxiMDRmVllNTGVDbEltMDlodFdUaHBmcWdPdjlIdmVvTFNmMlNLRlctc1BtcVdIdFU4LUViNFRaY0NJdU9BQlVkdktrdHl0djBwZkZaSUR2NzByYjdrNTJqZ21GMjc3R05VbFBrM2F2dW1ZWjZ1U1dHRXI4c3lENndJQXFCRGZXOVFfQlAwX3FnSmtjNG04U3V2QQ?oc=5" target="_blank">Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMSeligman Ventures doubles capital to $1 billion as AI boom revives hardware bets - Reuters
Seligman Ventures doubles capital to $1 billion as AI boom revives hardware bets Reuters
September 28, 2026 at 05:00 PMWalgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports - reuters.com
Walgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports reuters.com
September 30, 2026 at 08:14 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMAMD to buy Fei-Fei Li's World Labs in $8.2 billion bet on 'physical AI' - Reuters
AMD to buy Fei-Fei Li's World Labs in $8.2 billion bet on 'physical AI' Reuters
September 28, 2026 at 11:18 PM